Clinical Trial Update: Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast [Phase 2]

View source ↗

Summary

Phase 2 trial testing an active form of tamoxifen (4-hydroxytamoxifen) delivered through the breast skin to treat ductal carcinoma in situ (DCIS) that is estrog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Carcinoma in Situ
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• 4-hydroxytamoxifen (4-hydroxytamoxifen)

Snippet

Sponsor: Northwestern University | Conditions: Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive | Phase 2 | Status: COMPLETED | Results posted: 2024-12-18